Tango Therapeutics annual capital expenditures (capex)
2020
2021
2022
2023
2024
2025
Tango Therapeutics Capital Expenditures (CapEx) Growth & History (TNGX)
Tango Therapeutics's capital expenditures (capex) was $1.0M for fiscal 2025.
View full Tango Therapeutics company overviewTango Therapeutics annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.0M | $294,000 | +38.99% |
| 2024 | 2024-12-31 | $754,000 | −$772,000 | −50.59% |
| 2023 | 2023-12-31 | $1.5M | −$6.2M | −80.16% |
| 2022 | 2022-12-31 | $7.7M | $5.9M | +318.73% |
| 2021 | 2021-12-31 | $1.8M | $731,000 | +66.09% |
| 2020 | 2020-12-31 | $1.1M | — | — |
Tango Therapeutics quarterly capital expenditures (capex)
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $20,000 | −$604,000 | −96.79% |
| Q1 2026 | 2026-03-31 | $2,000 | −$49,000 | −96.08% |
| Q4 2025 | 2025-12-31 | $222,000 | $98,000 | +79.03% |
| Q3 2025 | 2025-09-30 | $151,000 | $36,000 | +31.30% |
| Q2 2025 | 2025-06-30 | $624,000 | $304,000 | +95.00% |
| Q1 2025 | 2025-03-31 | $51,000 | −$144,000 | −73.85% |
| Q4 2024 | 2024-12-31 | $124,000 | −$102,000 | −45.13% |
| Q3 2024 | 2024-09-30 | $115,000 | $99,000 | +618.75% |
| Q2 2024 | 2024-06-30 | $320,000 | −$344,000 | −51.81% |
| Q1 2024 | 2024-03-31 | $195,000 | −$425,000 | −68.55% |
| Q4 2023 | 2023-12-31 | $226,000 | −$815,000 | −78.29% |
| Q3 2023 | 2023-09-30 | $16,000 | −$3.3M | −99.51% |
| Q2 2023 | 2023-06-30 | $664,000 | −$1.1M | −63.34% |
| Q1 2023 | 2023-03-31 | $620,000 | −$941,000 | −60.28% |
| Q4 2022 | 2022-12-31 | $1.0M | $345,000 | +49.57% |
| Q3 2022 | 2022-09-30 | $3.3M | $2.5M | +323.64% |
| Q2 2022 | 2022-06-30 | $1.8M | $1.6M | +796.53% |
| Q1 2022 | 2022-03-31 | $1.6M | $1.4M | +846.06% |
| Q4 2021 | 2021-12-31 | $696,000 | — | — |
| Q3 2021 | 2021-09-30 | $774,000 | — | — |
| Q2 2021 | 2021-06-30 | $202,000 | — | — |
| Q1 2021 | 2021-03-31 | $165,000 | — | — |
Tango Therapeutics capital expenditures (capex) trends
Over the last five fiscal years, Tango Therapeutics's capital expenditures (capex) decreased from $1.1M to $1.0M, a change of −$58,000. The latest reported quarter, Q2 2026, shows $20,000.
About the metric
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
Calculation and source
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Tango Therapeutics source filings ↗